The post Bitcocom. US spot Bitcoin ETFs saw $1. 1B in weekly outflows, the 4th-largest on record. Bitcoin price dropped 9. 9% to around $95,740 amid continuous ETF withdrawals. The spot Bitcoin exchange-traded funds in the United States have seen a hugely negative week of trading, with withdrawals of $1. 1 billion last week, which is their fourth-largest outflow period recorded. In fact, the big money pullout happened at the same time when the price of Bitcoin dropped by more than 9. 9% and was approximately $95,740 at the time of writing. It is the third week in a row that spot Bitcoin ETFs have had a flow of funds going in the opposite direction, which is a cause of worry about the demand for Bitcoin from institutional investors. Market Enters Critical Phase According to Matrixport, a crypto analytics platform, the recent market conditions can be understood as a “mini” bear market, gradually developing with reduced momentum and no significant catalysts for recovery. In its report, the company noted that the decline in ETF flows, the reduced exposure of long-term investors, and the unfavourable macroeconomic conditions have combined to make it difficult to maintain price rallies for a prolonged period. Consequently, decisions on the Federal Reserve policy will largely determine the path of Bitcoin, as per the Matrixport analysis shared on the social media platform X on Friday. The cryptocurrency market is currently at a critical juncture, where the next major move will be decided by the ability to hold important technical price levels and the reaction to macroeconomic signals. In fact, throughout 2025, inflows into a spot Bitcoin ETF and purchases made by Michael Saylor’s Strategy company were the main sources of demand for the digital asset market. Spot Solana ETFs, on the other hand, were less affected by the general market decline as they registered.
Author: admin
Xbox Partner Preview stream coming this week with a new look at James Bond game 007 First Light confirmed
Xbox Partner Preview stream coming this week with a new look at James Bond game 007 First Light confirmed
Pistons’ Cade Cunningham becomes 6th active NBA player with Nike signature shoe
Cade Cunningham’s star just keeps on getting brighter. The Detroit Pistons star guard added to his basketball resume when it was reported on Monday that he has reached a new contract with Nike that includes having his own signature shoe, per Shams Charania of ESPN. “Detroit Pistons superstar Cade Cunningham has reached a new six-year [.] The post Pistons’ Cade Cunningham becomes 6th active NBA player with Nike signature shoe appeared first on ClutchPoints.
Mike Vrabel responded to Cam Newton’s ‘fool’s gold’ assessment of the Patriots
Vrabel also discussed his mentality at having a second chance to be an NFL head coach. The post Mike Vrabel responded to Cam Newton’s ‘fool’s gold’ assessment of the Patriots appeared first on Boston. com.
Amid Bitcoin Slump, Strategy Expands Corporate Holdings
Key Highlights: Strategy bought 8, 178 BTC between November 10-16, 2025. The funding came from a €620 million preferred-stock.
Watts Water Technologies Inc. Completes Acquisition of Superior Boiler
NORTH ANDOVER, Mass.–(BUSINESS WIRE)–WATTS WATER TECHNOLOGIES INC. COMPLETES ACQUISITION OF SUPERIOR BOILER
Crypto to pump in Q4? Yeah, right. Why bulls got it wrong
The post Crypto to pump in Q4? Yeah, right. Why bulls got it wrong appeared com. For months, big-name crypto boosters promised an “unbelievable” fourth quarter (Q4) and they weren’t wrong, just not in the way they intended. Bitcoin, the industry’s top digital asset, has performed poorly since Q4 began. It hit a six-month low over the weekend as liquidity thinned across global markets. The coin dropped to the 92, 970 range on Sunday and has since hovered around 94, 900 at last check on Nov. 17. Summary Bitcoin, Ethereum, and Solana have all fallen sharply since Q4 began, with BTC down over 10% and ETH over 11%, defying typical seasonal gains. Crypto boosters forecasted massive rallies, but the market moved in the opposite direction. Risk-off sentiment, slowing institutional inflows, regulatory pressure, and macro uncertainty have cooled what many expected to be a broad-based year-end crypto rally. Bitcoin (BTC) has averaged 77% gains in the past fourth quarters, while Ethereum (ETH) typically climbs about 19%. Since last week, Bitcoin has been down over 10%, while Ethereum has been down over 11%. And Solana (SOL) is down over 24% since Q4 began and over 16% over the past seven days. A chorus of confident predictions The downturn is especially striking given the number of prominent figures across finance and crypto that hyped up crypto heading into Q4. American Bitcoin Corp. co-founder Eric Trump declared Q4 would be “unbelievable.” He was wrong. Analysts at JPMorgan and Citi also forecast a powerful year-end rally driven by ETF inflows, with Bitcoin targets ranging from $133,000 to $165,000. Asset manager VanEck went further, projecting Bitcoin at $180,000 by year-end 2025, alongside major surges in Ethereum and Solana. Influential voices in the crypto community chimed in too: market analyst Ted Pillows expected a 35% rally, commentator Scott Melker floated a path to $250,000, and X personality Ash Crypto predicted Bitcoin would race to.
ONE 173 post-fight breakdown: Marat Grigorian makes Rukiya Anpo pay for trash-talk with a three-round beatdown
Marat Grigorian proved that it’s never wise to poke the bear. Rukiya Anpo learned this lesson the hard way at ONE 173: Superbon vs. Noiri.
Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off
The post Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off appeared com. Recursion’s incoming CEO Najat Khan Recursion After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion cofounder and CEO Chris Gibson promised to develop 100 drugs in 10 years, thanks to the company’s use of AI in drug discovery. It’s been rocky. More than a decade on, Recursion still has not brought a single drug to market. Its shares have cratered 86% since its April 2021 IPO, giving it a market cap today of $2. 2 billion. Earlier this year, Recursion culled half of its pipeline of drugs and in June it cut its workforce by 20%, the third round of layoffs since August 2024. And its revenue for the latest 12 months (through September 30) shrank by one-third to $44 million from $65 million while its losses ballooned by nearly 90% to a staggering $716 million. But Najat Khan, who will take over as CEO on January 1 as Gibson steps back, likes doing hard things. “A lot of people when I went to Recursion said, ‘Changing the rules about how medicine is made is really hard.’ I’m like, ‘All right, challenge accepted,’” Khan told Forbes in her first interview since accepting the top job. “Is it going to work? Is it not? It is so worth a try, and rising up to that challenge, because 20 years into my career, we still have a 90% failure rate.” Khan joined Salt Lake City-based Recursion in April 2024 as head of R&D and chief commercial officer. Previously, she’d built Johnson & Johnson’s 250-person AI team from scratch as chief data science officer and global head of strategy for innovative medicine R&D. Khan has now been.
Rory McIlroy Makes History at Race to Dubai to Cap ‘Best Year’ of Career
Rory McIlroy won the DP World Tour’s Race to Dubai to cap off a season of five victories worldwide, including the Ryder Cup.








